Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
医学
卵巢癌
肿瘤科
内科学
癌症
第一行
作者
B.J. Monk,Maria Pilar Barretina-Ginesta,Bhavana Pothuri,Ignace Vergote,Whitney Graybill,Mansoor Raza Mirza,C. C. McCormick,Domenica Lorusso,Richard G. Moore,Gilles Freyer,Roisin E. O’Cearbhaill,Florian Heitz,David M. O’Malley,Andrés Redondo,Mark S. Shahin,Christof Vulsteke,William H. Bradley,Charlotte Aaquist Haslund,Dana M. Chase,Carmela Pisano
出处
期刊：Annals of Oncology [Elsevier BV] 日期：2024-09-14卷期号：35 (11): 981-992被引量：22
The phase III PRIMA/ENGOT-OV26/GOG-3012 trial met its primary endpoint. Niraparib first-line maintenance significantly prolonged progression-free survival (PFS) among patients with newly diagnosed advanced ovarian cancer that responded to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status. Final overall survival (OS) results are reported.
cdercder
归尘
斯寜
平常的毛豆
余味
827584450
YifanWang
bc
月下独酌42
nenoaowu
back you up
典雅问寒
科研小民工
yang
jyy
今天只做一件事
eee
Oracle
maox1aoxin
加菲丰丰
皖公网安备34019202002308
